Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.02 USD
-0.48 (-1.88%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $24.98 -0.04 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Cash flow Statements
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -82.67 | -14.86 | 4.13 | -23.98 | 27.19 |
Depreciation/Amortization & Depletion | 76.41 | 14.49 | 20.78 | 69.52 | 6.36 |
Net Change from Assets/Liabilities | -12.12 | -11.82 | -11.96 | -12.94 | -6.64 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.60 | 16.60 | -4.56 | -19.54 | 10.10 |
Net Cash From Operating Activities | -1.79 | 4.41 | 8.40 | 13.07 | 37.01 |
Property & Equipment | -5.43 | -7.49 | -5.14 | -1.63 | -2.83 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -0.48 | -94.60 | 0.00 |
Investments | 0.00 | 0.00 | 2.50 | 24.97 | 42.52 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -5.43 | -7.49 | -3.12 | -71.26 | 39.69 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -4.98 | 0.02 | 1.13 | 1.52 | -7.85 |
Issuance (Repayment) of Debt | 0.00 | -0.28 | -0.20 | -0.56 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.35 | -4.58 | -7.71 | -4.74 | -0.29 |
Net Cash from Financing Activities | -6.32 | -4.85 | -6.78 | -3.77 | -8.14 |
Effect of Exchange Rate Changes | 0.08 | -0.13 | 0.07 | 0.33 | -0.13 |
Net Change In Cash & Equivalents | -13.46 | -8.06 | -1.43 | -61.65 | 68.42 |
Cash at Beginning of Period | 86.33 | 94.39 | 95.82 | 157.46 | 89.04 |
Cash at End of Period | 72.87 | 86.33 | 94.39 | 95.82 | 157.46 |
Diluted Net EPS | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 |
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -4.60 | -4.51 | -82.67 | -19.67 | -13.09 |
Depreciation/Amortization & Depletion | 4.12 | 2.06 | 76.41 | 10.64 | 7.10 |
Net Change from Assets/Liabilities | -12.22 | -4.18 | -12.12 | -9.51 | -12.95 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.51 | 6.50 | 16.60 | 13.11 | 7.03 |
Net Cash From Operating Activities | -1.20 | -0.13 | -1.79 | -5.43 | -11.91 |
Property & Equipment | -5.21 | -1.81 | -5.43 | -3.59 | -2.85 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -5.21 | -1.81 | -5.43 | -3.59 | -2.85 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -1.29 | 0.02 | -4.98 | -4.96 | -4.96 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.09 | -2.30 | -1.35 | -1.70 | -1.59 |
Net Cash from Financing Activities | -3.38 | -2.27 | -6.32 | -6.67 | -6.56 |
Effect of Exchange Rate Changes | -0.26 | -0.03 | 0.08 | 0.00 | 0.06 |
Net Change In Cash & Equivalents | -10.05 | -4.24 | -13.46 | -15.68 | -21.26 |
Cash at Beginning of Period | 72.87 | 72.87 | 86.33 | 86.33 | 86.33 |
Cash at End of Period | 62.82 | 68.63 | 72.87 | 70.65 | 65.07 |
Diluted Net EPS | -0.01 | -0.31 | -4.29 | -0.45 | -0.19 |